Cytodyn Inc (CYDY)

[JPG77]

I "had" many shares in another biotech stock that was in their phase 3 trials, and due to the many complaints about transparency, the CEO gave in to the stockholders' demands and started giving monthly enrollments updates. The pps was immediately pummeled by the shorts, and every month by short attacks following each monthly enrollment update. For this reason, the company then had to do a 1/12 reverse split to stay on the NYSE, and now they're struggling to raise cash to complete their P3 due to the very low pps - and all of this while experiencing positive results throughout their P3. When the shorts know that a trial has a way to go to completion, and they can estimate the completion date, they'll pummel it due to the low risk.